• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Epigenetic I

  2026-07-10

  Discover how the Phosphatase Inhibitor Cocktail (2 Tubes, 100X) preserves protein phosphorylation and enables accurate dissection of phospho-signaling and epigenetic regulation. This article uniquely connects biochemical assay workflows with recent advances in understanding MAPK pathway control and histone modification.

• Temafloxacin in Advanced Antibacterial Research Workflows

  2026-07-09

  Temafloxacin, a fluoroquinolone broad-spectrum antibacterial agent, empowers researchers to dissect Gram-positive, Gram-negative, and intracellular infection models with exceptional precision. This article delivers practical protocols, troubleshooting guidance, and comparative insights for maximizing experimental reliability in respiratory, mycobacterial, and complex infection research.

• KN-62 Enables Precision CaMKII Inhibition in Cell Signaling

  2026-07-09

  KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, stands out as a highly selective CaMKII inhibitor for dissecting calcium-dependent signaling and metabolic regulation. This article details experimental workflows, troubleshooting strategies, and advanced applications that maximize the interpretive power of KN-62 in cell biology and metabolic research.

• Flubendazole in Autophagy Modulation: Protocols & Research I

  2026-07-08

  Flubendazole (methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate) is redefining autophagy modulation research with its robust DMSO solubility and high purity, enabling deeper mechanistic studies in cancer and fibrosis models. This guide offers practical workflows, troubleshooting insights, and a bridge to the latest findings on metabolic regulation in hepatic stellate cells.

• Aztreonam: Monocyclic β-Lactam Antibiotic Workflows & Insigh

  2026-07-08

  Aztreonam stands out as a synthetic monocyclic β-lactam antibiotic, uniquely targeting Gram-negative aerobic bacteria and enabling advanced experimental workflows in resistance and metabolic research. This article distills protocol enhancements, troubleshooting strategies, and translational advantages for researchers leveraging Aztreonam in multidrug resistance studies.

• Ferritin-Based Hybrid Vaccine Targets Influenza and SARS-CoV

  2026-07-07

  This study introduces a ferritin-based hybrid protein particle vaccine co-displaying the M2e antigen of influenza A and S-protein tandem epitopes from SARS-CoV-2. The approach leverages ferritin's self-assembly to enhance immunogenicity and provides a scalable, versatile platform for next-generation combination vaccines.

• Aztreonam: Strategic Leverage in Gram-Negative Resistance Re

  2026-07-07

  This thought-leadership article examines the mechanistic underpinnings and translational significance of Aztreonam, a synthetic monocyclic β-lactam antibiotic, for researchers tackling multidrug-resistant Gram-negative bacteria. We integrate recent epidemiological findings, highlight experimental best practices, and propose strategic directions for leveraging Aztreonam in resistance modeling and pharmacological workflows.

• Hierarchical ROS-Responsive Nanoplatform for Diabetic Period

  2026-07-06

  This study presents a hierarchically targeted, ROS-responsive nanoparticle-hydrogel system that selectively repairs mitochondrial dysfunction in M1 macrophages, thereby disrupting the inflammatory cascade central to diabetic periodontitis. The approach demonstrates significant attenuation of periodontal tissue destruction and enhancement of bone regeneration, holding promise for targeted intervention in inflammation-driven comorbidities.

• Omeprazole (A2845): Practical Use in Gastric Acid Secretion

  2026-07-06

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for laboratory research on gastric acid secretion and antiulcer mechanisms. It is not suitable for diagnostic or medical applications, but is well-suited for peptic ulcer disease models and mechanistic studies of proton pump inhibition.

• Apigenin: Protocols and Innovations for Neurodegeneration an

  2026-07-05

  Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) is reshaping translational workflows for neurodegeneration and cancer research, offering robust HDAC inhibition and unique neuroprotective mechanisms. This article distills advanced protocol guidance, troubleshooting insights, and key findings from network medicine to empower reproducible, data-driven experimentation.

• Ceftolozane Sulfate: Mechanism, Benchmarks, and Research Int

  2026-07-04

  Ceftolozane sulfate is a time-dependent oxyimino cephalosporin with potent bactericidal activity against Pseudomonas aeruginosa and non-carbapenemase-producing Enterobacterales. Its stability against AmpC β-lactamases and defined PK/PD targets make it a robust tool for antibacterial research and clinical applications. Key benchmarks and protocol parameters facilitate reproducibility in pharmacodynamic studies.

• Proteasome Heterogeneity and Breast Cancer Subtype Markers

  2026-07-03

  This study uncovers subtype-specific heterogeneity in proteasome activity and composition across breast cancer subtypes, correlating these features with key molecular markers such as Ki67 and hormone receptors. The findings inform future strategies for designing proteasome-targeted or combinatorial therapies tailored to distinct breast cancer molecular profiles.

• PDK4-IN-1 Hydrochloride: Precision Modulation of Mitochondri

  2026-07-03

  Explore how PDK4-IN-1 hydrochloride, a pyruvate dehydrogenase kinase 4 inhibitor, enables advanced control of mitochondrial energy metabolism and cellular signaling. This article uncovers mechanistic insights, practical assay considerations, and the translational significance of selective PDK4 inhibition beyond existing guides.

• EAGLE-1 Phase 3: Oral Gepotidacin vs. Standard Therapy for G

  2026-07-02

  The EAGLE-1 phase 3 trial demonstrated that oral gepotidacin is non-inferior to the combination of intramuscular ceftriaxone and oral azithromycin in treating uncomplicated urogenital gonorrhoea. This large, multicentre study addresses the urgent need for new oral antibiotics against Neisseria gonorrhoeae and provides robust evidence for gepotidacin as a viable future therapeutic option.

• LLY507: Advancing Selective SMYD2 Inhibition for Translation

  2026-07-02

  Explore how LLY507, a potent SMYD2 inhibitor, enables precise interrogation of cytoplasmic methylation and its impact on cancer proliferation and renal fibrosis. This article uniquely dissects SMYD2's substrate specificity and practical assay implications, offering advanced guidance for translational scientists.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page